In this Issue:
Australasian Lung Cancer Trials Group (ALTG)
Lung cancer in Australia
Learning from data
Where are the opportunities?
New frontiers in SABR
Optimising RT fractionation: NSCLC
RT and chemotherapy
RON/MST1R: mesothelioma biomarker?
NY-ESO-1 promoter methylation
Mediastinal staging in NSCLC
Genomics of NSCLC
Quality of care parameters at end of life
Genetics & adherence with lung cancer screening
Please login below to download this issue (PDF)